A novel biparatopic hybrid antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy

In the absence of a proven effective vaccine preventing infection by SARS-CoV-2, or a proven drug to treat COVID-19, the positive results of passive immune therapy using convalescent serum provide a strong lead. We have developed a new class of tetravalent, biparatopic therapy, 89C8-ACE2. It combine...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Xiaoniu Miao, Yi Luo, Xi Huang, Suki M. Y. Lee, Zhijun Yuan, Yongzhou Tang, Liandi Chen, Chao Wang, Fan Wu, Yifeng Xu, Wenchao Jiang, Wei Gao, Xuedong Song, Yao Yan, Tuling Pang, Cheng Chen, Yuefeng Zou, Weihui Fu, Liping Wan, Javier Gilbert-Jaramillo, Michael Knight, Tiong Kit Tan, Pramila Rijal, Alain Townsend, Joanne Sun, Xiaolin Liu, William James, Andy Tsun, Yingda Xu
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Taylor & Francis Group 2020-01-01
Цуврал:	mAbs
Нөхцлүүд:	Biparatopic neutralizing antibody antibody-ACE2 fusion COVID-19 SARS-CoV-2
Онлайн хандалт:	https://www.tandfonline.com/doi/10.1080/19420862.2020.1804241
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!